The failed Phase 3 trial severely damages fasedienol's probability of approval and the company's pipeline value. The post-hoc subgroup signal is unlikely to salvage the program without a costly new trial. With a $10M market cap and cash runway into 2027, the stock may see significant downside as the lead asset's path to market is now highly uncertain. Monitor for FDA meeting outcomes and potential financing needs.
Price Chart
Executive Summary
Vistagen announced that its PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder failed to meet the primary endpoint (p=0.427) and secondary endpoints in the overall population. A post-hoc analysis showed nominal statistical significance in a subgroup of patients with very severe social anxiety (p=0.036), but this is exploratory and not confirmatory. The company plans to meet with the FDA to discuss a potential registrational pathway involving a single future Phase 3 trial, but the lead program's path to approval is now highly uncertain, representing a material negative catalyst for this $10M market cap biotech.
Key Facts
- PALISADE-4 Phase 3 trial of fasedienol failed to meet the primary endpoint (p=0.427) and secondary endpoints in the overall population (n=238).
- Fasedienol LS mean SUDS change was -9.5 vs placebo -11.4, difference 1.9 (p=0.427), not statistically significant.
- A post-hoc analysis in a subgroup with very severe SAD (n=123) showed nominal statistical significance (p=0.036), but this is exploratory and not confirmatory.
- Company plans to meet with FDA to discuss a potential registrational pathway involving a single future multi-dose Phase 3 trial with LSAS as primary endpoint, using prior PALISADE-2 data as confirmatory evidence.
- Company expects cash resources to support operations into 2027.
- Market cap is approximately $10M with 0% analyst bullish rating (7 Hold, 1 Sell, 2 Strong Sell).
Financial Impact
Lead pipeline asset fasedienol failed Phase 3 primary endpoint, severely diminishing probability of regulatory approval and commercial value. The company's $10M market cap reflects the high risk, but this failure materially reduces the already-low probability of success for the only late-stage asset.
Risk Factors
- FDA may not accept a registrational pathway based on a single future Phase 3 trial with confirmatory evidence from prior trials, given the PALISADE-4 failure.
- Post-hoc subgroup analysis is not confirmatory and may not be accepted by regulators as evidence of efficacy.
- Company may need additional financing to fund a new Phase 3 trial, potentially causing dilution at depressed share prices.
- Pipeline is entirely early-stage (Phase 2) with no other late-stage assets to offset fasedienol's setback.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-046143 |
| Document: vtgnex99120260630.htm | 0001628280-26-046143 |
| Document: vtgnex99220260630.htm | 0001628280-26-046143 |
| Document: 0001628280-26-046143-index-headers.html | 0001628280-26-046143 |
| Document: 0001628280-26-046143-index.html | 0001628280-26-046143 |
| Document: 0001628280-26-046143.txt | 0001628280-26-046143 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.2676 $0.2432 | ▲ +9.12% | ▲ +7.13% | $0.2863 (−6.99%) |
Aug 14, 2026 7w ago | Press Release | $0.2676 $0.2432 | ▼ −9.12% | ▼ −7.13% | $0.2863 (+6.99%) |
Jul 31, 2026 9w ago | 8-K | $0.2410 $0.2529 | ▲ +4.94% | ▲ +1.95% | $0.2863 (+18.80%) |
Jun 30, 2026 13w ago | 8-K | $0.2260 $0.2302 | ▼ −1.86% | ▼ −2.89% | $0.2863 (−26.68%) |
Jun 17, 2026 15w ago | 8-K | $0.6702 $0.2400 | ▼ −64.19% | ▼ −64.72% | $0.2863 (−57.28%) |
Jun 15, 2026 15w ago | 8-K | $0.6900 $0.2461 | ▼ −64.33% | ▼ −64.53% | $0.2863 (−58.51%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.5731 $0.2492 | ▼ −56.52% | ▼ −58.41% | $0.2863 (−50.04%) |
Jun 9, 2026 16w ago | 8-K | $0.5351 $0.2492 | ▼ −53.43% | ▼ −57.05% | $0.2863 (−46.50%) |
May 19, 2026 19w ago | 8-K | $0.6400 $0.6702 | ▲ +4.72% | ▲ +3.98% | $0.2863 (−55.27%) |
May 12, 2026 20w ago | 8-K | $0.6200 $0.5400 | ▼ −12.90% | ▼ −11.18% | $0.2863 (−53.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access